Results of a human clinical trial to study the effects of a water extract of cinnamon have showed beneficial effects in hyperglycemic subjects.
The study will be presented Monday, April 26, at the Federation of American Societies for Experimental Biology (FASEB) Annual Meeting in Anaheim, CA. The abstract has been published in the FASEB Journal, Volume 24: 722.1, April 2010.
The double-blind, placebo controlled study contained 137 patients and used CinSulin®, a water extract of cinnamon patented in several countries.
After 2 months, fasting glucose decreased (p<0.005) in the aqueous cinnamon extract-supplemented group (8.85 ± 0.36 to 8.19 ± 0.29 mmol/L) [159.3 to 147.42 mg/dL] compared with 8.57 ± 0.32 to 8.44 ± 0.34 mmol/L [154.26 to 151.92 mg/dL] in the placebo group (p=0.45).
Glucose levels two hours after a 75 g carbohydrate load also decreased (p<0.0001) in the supplemented group (15.09 ± 0.57 to 13.30 ± 0.55 mmol/L) [271.62 to 239.4 mg/dL]compared to 14.18 ± 0.60 to 13.74 ± 0.58 mmol/L [255.24 to 247.32 mg/dL] with placebo.
“This clinical trial adds to the growing evidence that aqueous cinnamon extract may be beneficial for insulin-resistant populations,” said Dr. Barbara Stoecker, Regents Professor of Nutritional Sciences at Oklahoma State University, and an author of the study.
CinSulin® is a registered trademark of Tang An Medical and covered by US Patent #6,200,569.
CinSulin is distributed in the U.S. by A.M. Todd Botanical Therapeutics and available in quality formulations sold through various dietary supplement distribution channels. For more information contact Matt Redd at the number below, or by email: [email protected]
To view the FASEB Journal: http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/722.1